Veeva's S&P 500 Debut: A New Era for Life Sciences Software

Veeva Systems, a life sciences software company, is set to join the S&P 500, replacing Coterra Energy. The company, known for its tools for drug makers, is migrating from Salesforce infrastructure to its own Vault platform, boosting margins and giving it full control over updates and pricing. Veevas development cloud for trials and regulations is sticky, with subscription revenue hitting $2.68 billion in fiscal 2026, up 17%. However, Salesforce is launching its own life sciences cloud, potentially sparking a price fight and squeezing Veevas premium valuation. Despite this, Veevas decade head start and trust from top pharma firms build a strong moat, positioning it well for the long game. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2f3d4074d8ccf223